News Medical on MSN

Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Statins emerge as potential cancer immunotherapy boosters

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.
News Medical

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
The Manila Times

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression ...
ascopubs.org

Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma ...

Adjuvant therapy with donafenib plus anti–PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study). This is an ASCO Meeting Abstract ...
Stocktwits on MSN

KZIA stock is rising today — what does its data for nuclear PD-L1 degrader show?

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...
ascopubs.org

Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non–Small Cell Lung Cancer Management With Cemiplimab

Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...